GlassScriptPhysician profile
Lori Kortkamp
NPI 1083249353
$2,697.18
in general payments reported to CMS, 2019-2025
25 companies · $685 in 2025
The $685 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $388 · 2023: $706 · 2024: $919 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $534.16 | 2023-2025 | Veozah |
| Amgen INC. | $395.06 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $182.23 | 2022-2024 | Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $174.24 | 2022-2024 | |
| Novo Nordisk INC | $161.59 | 2022-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $142.79 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $127.68 | 2022-2024 | Jynarque |
| Sanofi-Aventis U.S. LLC | $127.58 | 2024-2025 | |
| Pfizer INC. | $105.78 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.51 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $89.92 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.21 | 2022-2024 | Jardiance |
| Insulet Corporation | $82.78 | 2025 | Omnipod |
| Hologic Sales and Service, LLC | $68.63 | 2022-2024 | Aptima |
| Abbvie INC. | $54.32 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $46.57 | 2023 | Prehevbrio |
| Phadia US INC. | $42.37 | 2024-2025 | Immunocap |
| Phathom Pharmaceuticals, INC. | $41.35 | 2024 | Voquezna |
| Pharmaessentia USA Corporation | $23.94 | 2025 | Besremi |
| Organon LLC | $22.48 | 2023 | |
| Sanofi Pasteur INC. | $20.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.20 | 2022 | |
| Dexcom, INC. | $18.96 | 2025 | Dexcom G6 Transmitter |
| Abiomed | $16.12 | 2023 | Impella |
| Seqirus USA INC | $15.30 | 2024 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kortkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.